{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+arm&page=25",
    "query": {
      "intervention": "Study arm",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 30991,
    "total_pages": 3100,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+arm&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+arm&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T15:12:51.670Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02063698",
      "title": "Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "auranofin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2014-02-19",
      "completion_date": "2016-11-11",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02063698"
    },
    {
      "nct_id": "NCT02955121",
      "title": "IU Health Krannert Personalized Medicine Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Prescriber Access to Genetic Information",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2016-11",
      "completion_date": "2020-01-15",
      "has_results": false,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955121"
    },
    {
      "nct_id": "NCT04209114",
      "title": "A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Bladder Tumor",
        "Muscle-Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radical cystectomy (RC)",
          "type": "PROCEDURE"
        },
        {
          "name": "Bempegaldesleukin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2020-02-05",
      "completion_date": "2023-06-07",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 15,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04209114"
    },
    {
      "nct_id": "NCT05789706",
      "title": "Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Diabete Type 2"
      ],
      "interventions": [
        {
          "name": "Dayamed Arthur a novel intelligent medication adherence platform",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Sierra Nevada Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-03-24",
      "completion_date": "2023-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-29",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789706"
    },
    {
      "nct_id": "NCT06244004",
      "title": "FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Sensitive Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Antiandrogen Therapy",
          "type": "DRUG"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cytotoxic Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "FDG-Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 125,
      "start_date": "2024-02-18",
      "completion_date": "2028-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "DeKalb",
          "state": "Illinois"
        },
        {
          "city": "Geneva",
          "state": "Illinois"
        },
        {
          "city": "Oak Brook",
          "state": "Illinois"
        },
        {
          "city": "Orland Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06244004"
    },
    {
      "nct_id": "NCT06259630",
      "title": "Nicotine Virtual Reality Conditioned Place Preference",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nicotine Addiction",
        "Nicotine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Nicotine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11-03",
      "completion_date": "2018-06-22",
      "has_results": false,
      "last_update_posted_date": "2024-02-14",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06259630"
    },
    {
      "nct_id": "NCT02579967",
      "title": "Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary T-cell Immunodeficiency Disorders",
        "Common Variable Immunodeficiency",
        "Immune System Diseases",
        "Autoimmune Lymphoproliferative",
        "Lymphoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "Immunosuppression Only Conditioning -Closed with amendment L",
          "type": "DRUG"
        },
        {
          "name": "Reduced Intensity Conditioning",
          "type": "DRUG"
        },
        {
          "name": "Myeloablative Conditioning-Closed with amendment L",
          "type": "DRUG"
        },
        {
          "name": "GVHD Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Allo BMT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "4 Years to 75 Years"
      },
      "enrollment_count": 354,
      "start_date": "2015-11-19",
      "completion_date": "2036-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579967"
    },
    {
      "nct_id": "NCT07629167",
      "title": "Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acneiform Drug Eruption",
        "Acneiform Eruptions"
      ],
      "interventions": [
        {
          "name": "Isotretinoin",
          "type": "DRUG"
        },
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Blood specimen collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Photographs of Rash",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stool Specimen collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "12 Years to 39 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-08-30",
      "completion_date": "2030-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07629167"
    },
    {
      "nct_id": "NCT05406700",
      "title": "Niraparib In Recurrent IDH 1/2 Gliomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Low-grade Glioma",
        "IDH2 Gene Mutation",
        "Recurrent Glioma",
        "IDH1 Mutation",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Resection/Treatment with Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2023-05-18",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05406700"
    },
    {
      "nct_id": "NCT00477607",
      "title": "Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ototoxicity",
        "Unspecified Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "alpha-lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "Audiology",
          "type": "BEHAVIORAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "BIOLOGICAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2007-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-03-07",
      "last_synced_at": "2026-11-22T15:12:51.670Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477607"
    }
  ]
}